Total: $1,315.7M

ADC Therapeutics SA

Lausanne, Switzerland

$200.00

N/A

$200M in a private round from existing and new investors, including Auven Therapeutics, Redmile, the Wild Family Office and Astrazeneca plc

10/23/17

Adgero Biopharmaceuticals Holdings Inc.

Princeton, N.J.

$3.40

N/A

Warrant tender offer to exercise certain categories of existing warrants; it issued 1.36M shares of common stock and raised total gross proceeds from the warrant exercises of approximately $3.4M

10/2/17

Antabio SAS

Labege, France

$8.60

Series A

€7.3M (US$8.6M) series A financing with subscriptions from investment funds IXO Private Equity, Irdi Soridec Gestion, Galia Gestion and from the company's historical investors, including former president of OM Pharma, Christophe Ricard

10/17/17

Appili Therapeutics Inc.

Halifax, Nova Scotia

$3.00

N/A

$3M in a private placement financing, which included investments from new and current investors including Innovacorp, Nova Scotia's early stage venture capital organization

10/24/17

Azura Ophthalmics Ltd.

Tel Aviv, Israel

$16.00

Series B

$16M in a series B round led by a syndicate of Orbimed, TPG Biotech and Brandon Capital's Medical Research Commercialisation Fund, with participation from existing investor Ganot Capital

10/11/17

Cullinan Oncology LLC

Cambridge, Mass.

$150.00

Series A

$150M series A co-led by MPM Capital and F2 Ventures

10/4/17

Cydan

Cambridge, Mass.

$34.00

N/A

$34M from new investor Longitude Capital, and existing investor, New Enterprise Associates, which led the round, along with Pfizer Venture Investments, Alexandria Venture Investments and Lundbeckfond Ventures

10/18/17

Forty Seven Inc.

Menlo Park, Calif.

$75.00

Series B

$75M series B financing led by new investor Wellington Management Company LLP with participation from existing investors Clarus, Lightspeed Venture Partners, Sutter Hill Ventures and GV

10/19/17

Gemini Therapeutics Inc.

Cambridge, Mass.

$42.50

Series A

$42.5M series A round co-led by Atlas Venture, Lightstone Ventures and Orbimed

10/18/17

Harmony Biosciences LLC

Plymouth Meeting, Pa.

$270.00

N/A

$270M in an equity financing from Valor Equity Partners, Fidelity Management & Research Co., HBM Healthcare Investments, Vivo Capital, Venbio Partners, Novo Holdings and Nan Fung Life Sciences

10/9/17

Immatics AG

Tuebingen, Germany

$58.00

Series E

$58M in a series E round that brought in Amgen Inc. as a new investor

10/5/17

Impact Biomedicines

San Diego

$22.50

Series A

$22.5M series A financing from Medicxi

10/16/17

Inezyne Technologies Inc.

Tampa, Fla.

$10.00

Series A

$10M series A preferred round led by existing investor Gaston Capital Healthcare Fund. The company has two clinical-stage programs: IT-139, a cancer resistance pathway (CRP) inhibitor for the treatment of pancreatic, gastric and BRAF-mutated cancers (including BRAF-mutated melanoma, lung cancer and thyroid cancer) in combination with existing anti-cancer therapies, and IT-141, a topoisomerase I (TOP-I) inhibitor for the treatment of colorectal and breast cancers.

10/9/17

Inflarx GmbH

Jena, Germany

$55.00

Series D

$30M in a series D round from Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC, plus additional undisclosed investors; the transaction also involved a $25M secondary share sale

10/16/17

KSQ Therapeutics

Cambridge, Mass.

$76.00

Series A

$76M in two financing rounds, with the latest led by Flagship Pioneering and joined by founding investor Polaris Partners, Arch Venture Partners and Alexandria Equities

10/3/17

Kymera Therapeutics LLC

Cambridge, Mass.

$30.00

Series A

$30M in a series A round led by Atlas Venture, with participation from Lilly Ventures and Amgen Ventures

10/31/17

Navire Pharma

Palo Alto, Calif.

$30.00

N/A

$30M launch money from Bridgebio Pharma Inc.

10/5/17

Palleon Pharmaceuticals Inc.

Waltham, Mass.

$47.60

Series A

$47.6M in a series A round led by SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures and Abbvie Ventures

10/5/17

Panoptica Inc.

Bernardsville, N.J.

$11.00

Series B

$11M in a series B financing provided by Third Rock Ventures and SV Health Investors (formerly SV Life Sciences)

10/9/17

Recursion Pharmaceuticals Inc.

Salt Lake City

$60.00

Series B

$60M series B led by Data Collective; prior institutional investors, such as Lux Capital, Obvious Ventures, Advantage Capital, Felicis, Epic and AME also participated, alongside new investors Mubadala, Menlo Ventures, CRV, Two Sigma and angel investors

10/4/17

Spruce Biosciences Inc.

San Francisco

$20.00

Series A

$20M from a series A completed in 2016, but just announced, and led by Novo Holdings A/S, with additional investment from Riverwest Venture Partners

10/13/17

Umecrine Cognition AB

Stockholm

$2.50

N/A

SEK20M (US$2.5M) round from Karolinska Development AB, and participants Förvaring AB, Stiftelsen Norrlandsfonden and company founder Torbjörn Bäckström

10/5/17

Virionhealth Ltd.

Coventry, U.K.

$17.00

Series A

£13M (US$17M) in series A funding led by Abingworth LLP

10/13/17

Visterra Inc.

Cambridge, Mass.

$23.60

Series C

$23.6M in the second part of a series C round totaling $46.7M; $23.1M was raised in June 2016; existing investors, Bill & Melinda Gates Foundation, MRL Ventures Fund, Vertex Venture Holdings Ltd., Polaris Partners, Flagship Pioneering, Omega Funds, Cycad Group, Alexandria Venture Investments – as well as new investors, Serum Institute of India Pvt. Ltd., CTI Life Sciences and Allegheny Financial Group, participated

10/6/17

Ymabs Therapeutics Inc.

New York

$50.00

N/A

$50M led by HBM Healthcare Investments and supported by current shareholders

10/25/17

Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.